(Q35624530)

English

Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Patrick J Mansky

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jean Grem

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dawn B Wallerstedt

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Brian P Monahan

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Marc R Blackman

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Integrative Cancer Therapies

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

345-352

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Mistletoe treatment for cancer review of controlled trials in humans

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Mistletoe lectins and their A and B chains

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Interactions between herbal medicines and prescribed drugs: a systematic review

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Evaluation of commercial ginseng products

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Variations in alkaloid content of herbal products containing goldenseal

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

PC-SPES--a lesson for future dietary supplement research

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1177%2F1534735403259061

21 January 2018

Identifiers

10.1177/1534735403259061

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

release_oqclawrndfee7eig3fnvitipri

1 reference

https://api.fatcat.wiki/v0/release/oqclawrndfee7eig3fnvitipri

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35624530&oldid=1836802370"